ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

stapokibart

Also written as “CM310”, “Stapokibart” and “Stapokibart injection”.

Its studies are mostly in Dermatitis, Atopic · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Nasal Polyps · Asthma, led by 3 companies.

Drug pageStapokibart: every studyAll 36 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 17, 202229 company-led studies, 11 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Keymed Biosciences246 open or runningphase 3since Feb 17, 2022Mar 12, 2021Feb 2027phase 3 · NCT07106372
Chengdu Kangnuoxing Biopharma,Inc.its history only33 open or runningphase 3since Sep 30, 2025Sep 30, 2025Dec 2026phase 3 · NCT07678931
CSPC Pharmaceutical Groupits history only22 open or runningphase 3since Feb 27, 2023Feb 27, 2023Apr 29, 2032phase 3 · NCT06547333

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Keymed Biosciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Mar 12, 2021.

  1. Jan 19, 2023Named stapokibartINNProposed as its International Nonproprietary Name in WHO's List 128 · before, CM310
  2. Jan 27, 2023Phase 2 study in Dermatitis, AtopicNCT05715320 · 160 enrolled · China
  3. Jun 2, 2023Phase 3 study in Rhinitis, AllergicNCT05908032 · 108 enrolled · China
  4. Jun 8, 2023Phase 2 study in Rhinitis, AllergicNCT05908721 · 100 enrolled · China
  5. Oct 30, 2023Phase 2 study in Dermatitis, AtopicNCT06116565 · 263 enrolled · China
  6. Nov 29, 2023Phase 2 study in Dermatitis, AtopicNCT06162507 · 24 enrolled · China
  7. Nov 29, 2023Phase 1 study in HealthyNCT06161090 · 33 enrolled · China
  8. Dec 4, 2023Phase 2 study in Rhinitis, Allergic, SeasonalNCT06171074 · 100 planned · China
  9. Dec 5, 2023Phase 1 study in HealthyNCT06171048 · 236 planned · China
  10. Feb 18, 2024Phase 3 study in Dermatitis, AtopicNCT06277765 · 180 enrolled · China
  11. May 16, 2024Phase 3 study in Prurigo NodularisNCT06424470 · 200 enrolled · China
  12. Jul 2, 2024Phase 3 study in Dermatitis, AtopicNCT06495229 · 180 enrolled · China
  13. Jul 24, 2024Phase 2 study in Rhinitis, AllergicNCT06525597 · 120 planned · China
  14. Apr 30, 2025Phase 3 study in Dermatitis, AtopicNCT06956196 · 240 planned · China
  15. Aug 5, 2025Phase 3 study in Dermatitis, AtopicNCT07106372 · 240 planned · China

Ahead

  1. Feb 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT07106372

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 24 Keymed Biosciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07106372Dermatitis, Atopic · China3Not yet recruitingFeb 2027240
NCT06956196Dermatitis, Atopic · China3Not yet recruitingMay 2026240
NCT06525597Rhinitis, Allergic · China2RecruitingOct 30, 2025120
NCT06495229Dermatitis, Atopic · China3Active, not recruitingAug 30, 2026180
NCT06424470Prurigo Nodularis · China3CompletedFeb 11, 2026200
NCT06277765Dermatitis, Atopic · China3CompletedJan 23, 2025180
NCT06171048Healthy · China1Not yet recruitingApr 30, 2025236
NCT06171074Rhinitis, Allergic, Seasonal · China2Not yet recruitingMar 30, 2025100
NCT06162507Dermatitis, Atopic · China2CompletedJul 4, 202424
NCT06161090Healthy · China1CompletedJan 13, 202033
NCT06116565Dermatitis, Atopic · China2CompletedNov 26, 2025263
NCT05908721Rhinitis, Allergic · China2CompletedDec 10, 2023100
NCT05908032Rhinitis, Allergic · China3CompletedDec 4, 2023108
NCT05715320Dermatitis, Atopic · China2CompletedJul 18, 2024160
NCT05702450Healthy · China1CompletedJul 26, 2023240
NCT05579925Dermatitis, Atopic · China2CompletedJul 28, 202324
NCT05452343Chronic Pruritus of Unknown Origin2UNKNOWNMar 1, 202450
NCT05265923Dermatitis, Atopic · China3CompletedOct 31, 2023500
NCT05186909Asthma · China2CompletedSep 13, 202352
NCT05131464Chronic Rhinosinusitis With Nasal Polyps · China2CompletedJan 31, 202446
NCT04893707Dermatitis, Atopic · China2CompletedFeb 3, 2023127
NCT04893941Moderate-to-severe Atopic Dermatitis · China2CompletedJan 22, 202139
NCT04805411Dermatitis, Atopic · China2CompletedNov 8, 2021120
NCT04805398Disease · China2CompletedMar 18, 202256

How it is read

Names in the registry

  • “CM310”, 22 entries
  • “Stapokibart”, 2 entries
  • “Stapokibart injection”, 2 entries
  • “Stapokibatrt”, 2 entries
  • “Stapokibart Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.